Company registration number 03561960 (England and Wales)
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
COMPANY INFORMATION
Directors
B Love
D Jones
Secretary
Resolis Limited
Company number
03561960
Registered office
1 Park Row
Leeds
United Kingdom
LS1 5AB
Auditor
Johnston Carmichael LLP
7-11 Melville Street
Edinburgh
United Kingdom
EH3 7PE
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3 - 4
Directors' responsibilities statement
5
Independent auditor's report
6 - 9
Group statement of comprehensive income
10
Group balance sheet
11
Company balance sheet
12
Group statement of changes in equity
13
Company statement of changes in equity
14
Group statement of cash flows
15
Notes to the financial statements
16 - 30
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 1 -

The directors present the strategic report for the year ended 31 December 2024.

Review of the business

The principal activity of the group is undertaking a Private Finance Initiative (PFI) concession contract at the Cumberland Infirmary, Carlisle.

 

The PFI concession managed by the group is in a mature operational stage and continues to operate broadly in line with long term operational plans.

 

In addition to the core concession management, the group manages the delivery of capital variation projects for the Trust on a pass-through basis.

 

As shown in the group’s profit and loss account on page 10 the group’s turnover increased by £1.7m (2023: increased by £1.9m) mainly due to higher RPI and higher value of variations conducted in the year. The operating profit decreased by £1.1m (2023: increased by £0.9m) for the same reason. Net assets at 31 December 2024 were £6.2m (2023: £3.3m).

 

Principal risks and uncertainties

Operational risks are monitored closely involving full-time representation on site through the group’s management services agent, periodic reporting by an independent Technical Assessor and regular dialogue with the executive team at the North Cumbria University Hospitals NHS Trust.

The group could be exposed to subcontractor failure to perform their obligations. This risk is being monitored closely but with principal focus being on the management and monitoring of ongoing service delivery.

Over the past few years, the group was engaged in a dispute with the NHS Trust over Retained Estate lifecycle expenditure. This dispute was taken to an adjudication court and the Expert's decision favoured the Trust. The group therefore decided to comply with the expert's determination to replace specific lifecycle items on the Retained Estate in line with the frequency set out in the underlying project agreement and informed the Trust.

The group has naturally reserved it’s right to dispute the Expert's decision, however it is not currently the intention to do so. The group has carried out a lifecycle review and costing exercise to ensure all additional lifecycle items on the Retained Estate determination are included in future lifecycle plans and the lender's technical advisor has been engaged in this process. The Retained Estate lifecycle work is now being delivered against the plan. The latest financial model includes a lifecycle cost profile which includes the agreed Retained Estate plan of works to ensure no current or future ratio breaches occur and this financial model has been approved by the lender.

 

Additionally as we approach the five year handback period, a condition survey is being undertaken by a specialist on behalf of the group who will produce a report detailing what lifecycle obligations the group is responsible for. The results from this survey is estimated to be concluded in October 25 and the company will be in a position to assess what lifecycle works are required up to the handback date. It is expected that the current model lifecycle cost profile will be sufficient to meet these requirements.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -

Financial risk management

The group has exposure to a variety of financial risks which are managed with the purpose of minimising any potential adverse effect on the group’s performance. The directors have policies for managing each of these risks and they are summarised below:

 

Interest rate risk

The senior debt interest has been fixed through the use of fixed funding rates, plus a margin, as set out in note 13. In order to hedge against interest variations on its loan, the group entered into a fixed interest rate swap arrangement during 2010. The group’s exposure to interest rate fluctuation will continue to be monitored.

 

Inflation risk

The group’s project revenue and most of its costs were linked to inflation at the inception of the project, resulting in the project being largely insensitive to inflation. In order to hedge against inflation, the group entered into a fixed-rate 22 year RPI swap during 2005. The group’s exposure to inflationary fluctuation will continue to be monitored.

 

Liquidity risk

The group adopts a prudent approach to liquidity management by endeavouring to maintain sufficient cash and liquid resources to meet its obligations as they fall due.

 

Credit risk

The group receives its revenue from an NHS Trust and is not exposed to significant credit risk. Cash investments and swap arrangements are with institutions of a suitable credit quality.

 

Major maintenance replacement risk

The group takes the risk that its projections for ongoing major maintenance replacement of the building and relevant equipment are adequate. These projections have been agreed with third parties and are subject to regular review by the directors.

Key performance indicators

The group’s operations are managed under the supervision of its shareholders and funders and are largely determined by the detailed terms of the PFI contract. This contract stipulates key performance criteria on operational activities as managed by the sub-contractor.

The group also monitors its results against the financial covenants stipulated in the finance agreements. DSCR (Debt Service Cover Ratio) is required to exceed 1.05 and LLC (Loan Life Cover) is required to exceed 1.10. The group exceeded these thresholds in the financial year.

On behalf of the board

B Love
Director
30 September 2025
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 3 -

The directors present their annual report and financial statements for the year ended 31 December 2024.

Principal activities

The principal activity of the group is undertaking a Private Finance Initiative (PFI) concession contract entered into on 26 September 1997 with the North Cumbria University Hospitals NHS Trust to refurbish certain existing hospitals, design and construct further hospital buildings and manage non-clinical support services at the hospitals. The project will run for a period of 45 years. The finance for the project is provided via a term loan facility of £64.8m due 2010-2029 (as detailed in note 13). Construction was completed in March 2000 and service operations have been provided since that date.

Future Developments

The directors expect the group’s activities to the remain unchanged for the foreseeable future.

Going concern

The directors have prepared detailed model forecasts incorporating the relevant terms of the PFI contract, subcontracts and credit agreements, and have adopted prudent assumptions in relation to economic and operational factors. In preparing these forecasts, the Directors have considered external economic factors, supply chain pressures and other global price increases, as well as the dispute with the Trust outlined in the Strategic Report.

The forecasts predict that the group will have sufficient cash resources to meet its liabilities as they fall due for a period of 12 months from the date of signing the financial statements.

Having considered the financial position of the group, its expected future cash flows and the ongoing support of the group’s senior lender, the directors have a reasonable expectation that the group will have adequate resources to continue to generate positive operating cashflows and have therefore prepared the financial statements on a going concern basis.

Results and dividends

The results for the year are set out on page 10.

Dividends of £2.2m were paid during the year (2023: £1.1m). Post year end dividends of £1.0m have also been paid.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Matthew Templeton
(Resigned 15 March 2024)
B Love
D Jones
Financial instruments

Details of financial instruments and financial risk management are included in the Strategic Report on page 2.

Statement of disclosure to auditor

Each director has taken steps that they ought to have taken as a director in order to make themselves aware of any relevant audit information and to establish that the group’s auditor is aware of that information. The directors confirm that there is no relevant information that they know of and of which they know the auditor is unaware.

Reappointment of auditor

The auditor, Johnston Carmichael LLP, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 4 -
On behalf of the board
B Love
Director
30 September 2025
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2024
- 5 -

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”, and applicable law).

 

Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and company, and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are also responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and company and enable them to ensure that the financial statements comply with the Companies Act 2006.

 

The directors are also responsible for safeguarding the assets of the group and company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
- 6 -
Opinion

We have audited the financial statements of Health Management (Carlisle) Holdings Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report and financial statements other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report and financial statements. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
- 7 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and the parent company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the parent company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below:

We assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations by considering their experience, past performance and support available.

All engagement team members were briefed on relevant identified laws and regulations and potential fraud risks at the planning stage of the audit. Engagement team members were reminded to remain alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

We obtained an understanding of the legal and regulatory frameworks that are applicable to the group and parent company, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements. The most relevant frameworks we identified include:

 

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
- 8 -

We gained an understanding of how the group and parent company is complying with these laws and regulations by making enquiries of management and those charged with governance. We corroborated these enquiries through our review of submitted returns and board meeting minutes.

We assessed the susceptibility of the group and parent company’s financial statements to material misstatement, including how fraud might occur, by meeting with management and those charged with governance to understand where it was considered there was susceptibility to fraud. This evaluation also considered how management and those charged with governance were remunerated and whether this provided an incentive for fraudulent activity. We considered the overall control environment and how management and those charged with governance oversee the implementation and operation of controls. In areas of the financial statements where the risks were considered to the higher, we performed procedures to address each identified risk. We identified a heightened fraud risk in relation to:

In addition to the above, the following procedures were performed to provide reasonable assurance that the financial statements were free of material fraud or error:

Our audit procedures were designed to respond to the risk of material misstatements in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve intentional concealment, forgery, collusion, omission or misrepresentation. There are inherent limitations in the audit procedures performed and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we are to become aware of it.

 

 

Use of our report

This report is made solely to the company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company’s members as a body, for our audit work, for this report, or for the opinions we have formed.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
INDEPENDENT AUDITOR'S REPORT (CONTINUED)
TO THE MEMBERS OF HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
- 9 -
Allison Dalton (Senior Statutory Auditor)
For and on behalf of Johnston Carmichael LLP
30 September 2025
Statutory Auditor
7-11 Melville Street
Edinburgh
United Kingdom
EH3 7PE
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
GROUP STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2024
- 10 -
2024
2023
Notes
£000
£000
Turnover
2
29,131
27,432
Cost of sales
(25,118)
(22,311)
Gross profit
4,013
5,121
Administrative expenses
(937)
(957)
Operating profit
3
3,076
4,164
Interest receivable and similar income
4
3,806
4,025
Interest payable and similar expenses
5
(1,920)
(2,264)
Profit before taxation
4,962
5,925
Tax on profit
6
(1,620)
(2,879)
Profit for the financial year
3,342
3,046
Other comprehensive income
Cash flow hedges gain arising in the year
2,295
1,409
Tax relating to other comprehensive income
(574)
(352)
Total comprehensive income for the year
5,063
4,103
All results in the current and prior years derive from the principal activities of the group wholly undertaken in the United Kingdom and which are continuing.
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
GROUP BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 11 -
2024
2023
Notes
£000
£000
£000
£000
Current assets
Debtors falling due after more than one year
9
29,826
34,335
Debtors falling due within one year
9
17,086
15,348
Cash at bank and in hand
8,573
11,493
55,485
61,176
Creditors: amounts falling due within one year
10
(21,744)
(20,239)
Net current assets
33,741
40,937
Creditors: amounts falling due after more than one year
11
(26,338)
(36,557)
Provisions for liabilities
Deferred tax liability
13
1,229
1,067
(1,229)
(1,067)
Net assets
6,174
3,313
Capital and reserves
Called up share capital
14
841
841
Hedging reserve
15
(5,868)
(7,588)
Profit and loss reserves
15
11,201
10,060
Total equity
6,174
3,313

.

The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
30 September 2025
B Love
Director
Company registration number 03561960 (England and Wales)
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
COMPANY BALANCE SHEET
AS AT 31 DECEMBER 2024
31 December 2024
- 12 -
2024
2023
Notes
£000
£000
£000
£000
Fixed assets
Investments
7
841
841
Current assets
Debtors
9
2
2
Cash at bank and in hand
3
3
5
5
Net current assets
5
5
Net assets
846
846
Capital and reserves
Called up share capital
14
841
841
Profit and loss reserves
15
5
5
Total equity
846
846

As permitted by s408 Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s profit for the year was £2,202,000 (2023: £1,115,000).

The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
30 September 2025
B Love
Director
Company registration number 03561960 (England and Wales)
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
GROUP STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 13 -
Share capital
Hedging reserve
Profit and loss reserves
Total
Notes
£000
£000
£000
£000
Balance at 1 January 2023
841
(8,645)
8,129
325
Year ended 31 December 2023:
Profit and total comprehensive income
-
-
3,046
3,046
Other comprehensive income
-
1,409
-
1,409
Tax relating to other comprehensive income
-
(352)
-
0
(352)
Dividends paid
-
-
(1,115)
(1,115)
Balance at 31 December 2023
841
(7,588)
10,060
3,313
Year ended 31 December 2024:
Profit and total comprehensive income
-
-
3,342
3,342
Other comprehensive income
-
2,295
-
2,295
Tax relating to other comprehensive income
-
(574)
-
0
(574)
Dividends paid
-
-
(2,202)
(2,202)
Balance at 31 December 2024
841
(5,868)
11,201
6,174
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
COMPANY STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2024
- 14 -
Share capital
Profit and loss reserves
Total
Notes
£000
£000
£000
Balance at 1 January 2023
841
5
846
Year ended 31 December 2023:
Profit and total comprehensive income for the year
-
1,115
1,115
Dividends paid
-
(1,115)
(1,115)
Balance at 31 December 2023
841
5
846
Year ended 31 December 2024:
Profit and total comprehensive income
-
2,202
2,202
Dividends paid
-
(2,202)
(2,202)
Balance at 31 December 2024
841
5
846
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
GROUP STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 15 -
2024
2023
Notes
£000
£000
£000
£000
Cash flows from operating activities
Cash generated from operations
17
6,726
6,114
Income taxes (paid)/refunded
(4,618)
454
Net cash inflow from operating activities
2,108
6,568
Investing activities
Interest received
3,710
3,929
Net cash generated from investing activities
3,710
3,929
Financing activities
Repayment of bank loans
(4,616)
(4,487)
Interest paid
(1,920)
(2,264)
Dividends paid to equity shareholders
(2,202)
(1,115)
Net cash used in financing activities
(8,738)
(7,866)
Net (decrease)/increase in cash and cash equivalents
(2,920)
2,631
Cash and cash equivalents at beginning of year
11,493
8,862
Cash and cash equivalents at end of year
8,573
11,493
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 16 -
1
Accounting policies
Company information

The group’s principal activity is undertaking a Private Finance Initiative (PFI) concession contract entered into on 26 September 1997 with the North Cumbria University Hospitals NHS Trust to refurbish certain existing hospitals, design and construct further hospital buildings and manage and provide non-clinical support services at the hospitals.

The Company is a private company limited by shares and is incorporated in England. The Company’s registration number is 03561960.

The address of its registered office is 1 Park Row, Leeds, LS1 5AB, United Kingdom.

The group’s functional and presentation currency is the pound sterling. Monetary amounts in these financial statements are recorded to the nearest thousand.

The financial statements of Health Management (Carlisle) Holdings Limited have been prepared in compliance with applicable accounting and financial reporting standards in the United Kingdom, including FRS 102, ‘The Financial Reporting Standard applicable in the United Kingdom and the Republic of Ireland’ and the Companies Act 2006.

1.1
Accounting convention

These financial statements are prepared on a going concern basis, under the historical cost convention modified in respect of derivative financial instruments which are held at fair value.

The preparation of financial statements in conformity with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 2.

1.2
Basis of consolidation

The group’s financial statements consolidate the financial statements of Health Management (Carlisle) Holdings Limited and Health Management (Carlisle) Limited drawn up to 31 December each year.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 17 -
1.3
Going concern

The directors have prepared detailed model forecasts incorporating the relevant terms of the PFI contract, subcontracts and credit agreements, and have adopted prudent assumptions in relation to economic and operational factors. In preparing these forecasts, the Directors have considered external economic factors, supply chain pressures and other global price increases.

In preparing these forecasts, the Directors have also considered the dispute during the past few years with the NHS Trust over Retained Estate lifecycle expenditure. This dispute was taken to an adjudication court and the Expert's decision favoured the Trust. The group therefore decided to comply with the expert's determination to replace specific lifecycle items on the Retained Estate in line with the frequency set out in the underlying project agreement and informed the Trust.

The group has naturally reserved it’s right to dispute the Expert's decision, however it is not currently the intention to do so. The group has carried out a lifecycle review and costing exercise to ensure all additional lifecycle items on the Retained Estate determination are included in future lifecycle plans and the lender's technical advisor has been engaged in this process. The Retained Estate lifecycle work is now being delivered against the plan. The latest financial model includes a lifecycle cost profile which includes the agreed Retained Estate plan of works to ensure no current or future ratio breaches occur and this financial model has been approved by the lender.

 

Additionally as we approach the five year handback period, a condition survey is being undertaken by a specialist on behalf of the group who will produce a report detailing what lifecycle obligations the group is responsible for. The results from this survey is estimated to be concluded in October 25 and the group will be in a position to assess what lifecycle works are required up to the handback date. It is expected that the current model lifecycle cost profile will be sufficient to meet these requirements.

The forecasts predict that the group will have sufficient cash resources to meet its liabilities as they fall due for a period of 12 months from the date of signing the financial statements.

Having considered the financial position of the group, its expected future cash flows and the ongoing support of the group’s senior lender, the directors have a reasonable expectation that the group will have adequate resources to continue to generate positive operating cashflows and have therefore prepared the financial statements on a going concern basis.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 18 -
1.4
Turnover

Revenue is measured at the fair value of the consideration received or receivable and represents the amount receivable for goods supplied or services rendered, net of returns, discounts and rebates allowed by the group and value added taxes.

The group recognises income when it has fully fulfilled its contractual obligations. The group includes sales and purchase transactions related to variations under the original contract where the benefits and risks are retained by the group, within the financial statements as turnover and cost of sales. Where appropriate, income received under the PFI contract in respect of services provided during the operational phase of the contract is deferred to future periods in order to match those elements of income with the costs to which they relate. The turnover and cost of sales are recorded in the profit and loss account in the period in which the relevant costs are incurred.

Transactions to which the group does not have access to all the significant benefits and risks are excluded from the financial statements.

Finance debtor and interest receivable

The group has elected to take the exemption under FRS 102 paragraph 35.10 (i) to continue to apply its previous accounting treatment in respect of Service Concession Arrangements entered into prior to the date of transition to FRS 102. The costs incurred in constructing the assets have been treated as a finance debtor. This treatment arose from applying the guidance within previous UK GAAP which indicated that the project’s principal agreements transfer substantially all the risks and rewards relating to the property to the customer.

The finance debtor represents the costs arising on the construction of the assets including initial tender costs. During asset construction, finance debtor interest income is recognised on an accruals basis and is capitalised within the finance debtor receivable. Once the project reached its operational phase and was accepted by the customer a constant proportion of the planned net revenue arising from the project was allocated to remunerate the finance debtor. Imputed interest receivable is allocated to the finance debtor using a property specific rate to generate a constant rate of return over the life of the contract. Over the course of the contract term the finance debtor is expected to be fully repaid.

1.5
Fixed asset investments

Except as stated below, fixed asset investments are shown at cost less provision for impairment.

 

In the company balance sheet, investments in subsidiaries, acquired consideration is measured by reference to the nominal value only of the shares issued. Any premium is ignored.

1.6
Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

The group is obligated to keep cash reserves as at 31 March and 30 September in respect of requirements in the group’s funding agreements. The restricted cash balance, which is shown within the “cash at bank and on deposit” balance amounts to £5,144,000 (2023: £7,055,000) as at the balance sheet date.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 19 -
1.7
Financial instruments

Financial assets

Basic financial assets, including trade and other receivables and cash and bank balances are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Other financial assets are initially measured at fair value, which is normally the transaction price.

Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

 

Classification of financial liabilities

Financial liabilities

Basic financial liabilities, including trade and other payables, bank loans and loans from fellow group companies are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Fees paid on the establishment of loan facilities are recognised as transaction costs of the loan to the extent that it is probable that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw-down occurs. To the extent there is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a pre-payment for liquidity services and amortised over the period of the facility to which it relates.

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 20 -

Offsetting

Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Derivatives and Hedging arrangements

Derivatives, which may include interest rate swaps and RPI swaps, are not basic financial instruments.

Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or income as appropriate, unless they are included in hedging arrangements.

The group applies hedge accounting for transactions entered into to manage the cash flow exposures of borrowings. Interest rate swaps are held to manage the interest rate exposures and are designated as cash flow hedges of floating rate borrowings. RPI swaps are held to restrict the group’s exposure to the effect of RPI fluctuations on its income.

Changes in the fair values of derivatives designated as cash flow hedges, and which are effective, are recognised in other comprehensive income. Any ineffectiveness in the hedging relationship (being the excess of the cumulative change in fair value of the hedging instrument since inception of the hedge over the cumulative change in the fair value of the hedged item since inception of the hedge) is recognised in the profit and loss account.

The gain or loss recognised in other comprehensive income is reclassified to the profit and loss account in the same period in which the hedged transaction is recognised in the profit and loss account or when the hedge relationship ends. Hedge accounting is discontinued when the hedging instrument expires, no longer meets the hedging criteria, the forecast transaction is no longer highly probable, the hedged debt instrument is derecognised or the hedging instrument is terminated.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.8
Equity instruments

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividends and other distributions to the group’s shareholders are recognised as a liability in the financial statements in the period in which the dividends and other distributions are approved by the group’s shareholders. These amounts are recognised in the statement of changes in equity.

 

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 21 -
1.9
Taxation

Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the group operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date, where transactions or events that result in an obligation to pay more tax in the future or a right to pay less tax in the future have occurred at the balance sheet date.

Deferred tax is measured at the tax rates that are expected to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Deferred tax is measured on a non-discounted basis. Deferred tax assets are only recognised when it is considered more likely than not that there will be suitable taxable profits from which the future reversal of underlying timing differences can be deducted.

1.10

Exemptions for qualifying entities under FRS 102

FRS 102 allows a qualifying entity certain disclosure exemptions. The exemptions which the company has taken are:

i. the requirement to prepare a statement of cash flows on the basis that it is a qualifying entity and the consolidated statement of cash flows includes the company’s cash flows;

ii. certain financial instrument disclosures providing equivalent disclosures are included in the consolidated financial statements of the group in which the entity is consolidated;

iii. the requirement to disclose related party transactions, with the members of the same group, that are wholly owned;

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
Accounting policies
(Continued)
- 22 -
1.11

Critical accounting judgements and estimation uncertainty

Judgements, estimates and assumptions are based upon historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making judgements about carrying values of assets and liabilities that are not readily available from other sources. Actual results may subsequently differ from these estimates.

 

The judgements, estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to the accounting estimates made are recognised in the period in which the estimate is revised, if the revision affects

only that period, or in the period of revision and future periods if the revision affects both current and future periods.

 

Certain critical accounting judgements and estimates, adopted by management, in applying the group’s accounting policies are described below:

 

Finance Debtor

The group has elected to continue to apply its previous accounting treatment in respect of service concession arrangements entered into prior to the date of transition to FRS 102. This has resulted in the measurement of the finance debtor being different from that which would have resulted had the requirements of FRS 102 Section 34 been fully adopted. Accounting for service concession contracts and finance debtors requires estimation of service margins, finance debtors interest rates and the associated amortisation profile which are based on the forecast results of the PFI contracts over the respective concession length. See note 10 for the carrying value of the finance debtor.

 

Impairment of debtors

Management makes an estimate of the likely recoverable value of trade and other debtors by considering factors including the current credit rating, the ageing profile and the historical experience of the respective debtor. See note 10 for the carrying value of the debtors.

 

Treatment and measurement of derivatives

The directors have adopted a policy of cash flow hedge accounting for derivative financial instruments and have assessed that the group’s interest rate swap and RPI swap meet the criteria for hedge accounting under FRS 102. This allows unrealised gains and losses to be deferred in a cash flow hedge reserve and only recognised through the profit and loss account at the same time as the hedged cash flows.

 

The derivative financial instruments are recognised at fair value. The measurement of fair value is based on estimates of future market interest and inflation rates and will therefore be subject to change. The group has used a third party valuation to ascertain the fair value of such instruments.

2
Turnover and other revenue
2024
2023
£000
£000
Turnover analysed by class of business
Rendering of services
29,131
27,432
2024
2023
£000
£000
Other revenue
Interest income
3,806
4,025

Included in rendering of services are pass through variation capital works and other income invoiced to the Trust amounting to £5,229,000 (2023: £2,865,000). The equivalent costs is included in costs of sales.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 23 -
3
Operating profit

The group had 0 employees, other than the directors, during the year (2023: 0). The emoluments of the directors are paid by the controlling parties. The directors’ services to this company and to a number of fellow group companies are primarily of a non executive nature and their emoluments are deemed to be wholly attributable to the controlling parties. The controlling parties charged £134,000 (2023: £129,000) to the company in respect of these services.

 

The audit fee in respect of the group was £21,000 for the year (2023: £20,000), payable to Johnston Carmichael LLP.

4
Interest receivable and similar income
2024
2023
£000
£000
Interest income
Other interest income
3,806
4,025
5
Interest payable and similar expenses
2024
2023
£000
£000
Interest on financial liabilities measured at amortised cost:
Interest on bank overdrafts and loans
1,920
2,219
Other finance costs:
Unwinding of discount on provisions
-
45
Total finance costs
1,920
2,264
6
Taxation
2024
2023
£000
£000
Current tax
UK corporation tax on profits for the current period
2,032
3,216
Deferred tax
Origination and reversal of timing differences
(412)
(337)
Total tax charge
1,620
2,879
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
6
Taxation
(Continued)
- 24 -

Reconciliation of tax charge

For the year ended 31 December 2024, the UK corporation tax rate of 25% is applied.

The Finance Act 2021 was substantially enacted in May 2021 and has increased the corporation tax rate from 19% to 25% with effect from 1 April 2023.

The deferred taxation balances have been measured using the rates expected to apply in the reporting periods when the timing differences reverse.

The actual charge for the year can be reconciled to the expected charge based on the profit or loss and the standard rate of tax as follows:

 

2024
2023
£000
£000
Profit before taxation
4,962
5,925
Expected tax charge based on the standard rate of corporation tax in the UK of 25.00% (2023: 23.50%)
1,241
1,392
Tax effect of expenses that are not deductible in determining taxable profit
-
0
3
Adjustments in respect of prior years
6
1,205
Deferred tax relating to other comprehensive income
(574)
(352)
Timing differences
66
(90)
Adjustments to brought forward values
881
718
Re-measurement of deferred tax - change in UK rate
-
3
Taxation charge
1,620
2,879

In addition to the amount charged to the profit and loss account, the following amounts relating to tax have been recognised directly in other comprehensive income:

2024
2023
£000
£000
Reclassifications from equity to profit or loss:
Relating to cash flow hedges
(574)
(352)
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
6
Taxation
(Continued)
- 25 -

Tax losses

Deferred tax at 31 December 2024 has been calculated at 25%, the rate substantively enacted at the year end date.

 

Tax losses arising in previous years have been surrendered to the shareholder and former shareholder of the parent company by way of consortium relief (note 10). Amounts due from the former shareholder are now repaid in full. The shareholder is contracted to make payments to the group for such losses, surrendered at the rate which will be payable, as and when the group becomes liable to Corporation Tax which would not have been payable but for the surrender of the losses.

 

The group has agreed to defer these contractually due payments via loans which are repayable at the end of the concession or earlier on demand if the group’s cash flows require it.

 

Amounts of £1,676,762 (2023: £1,676,762) and £1,231,562 (2023: £1,231,562) have been included as consortium relief debtors and loans respectively (included within amounts owed by group undertakings in note 10) in respect of these payments receivable from the shareholder, representing valuations at current tax rates of the expected future cash inflows.

 

7
Fixed asset investments
Group
Company
2024
2023
2024
2023
Notes
£000
£000
£000
£000
Investments in subsidiaries
-
0
-
0
841
841

The company owns the entire ordinary issued share capital of Health Management (Carlisle) Limited, a company registered in England and Wales. The registered office of Health Management (Carlisle) Limited is 1 Park Row, Leeds, LS1 5AB. The principal activity of Health Management (Carlisle) Limited is described on page 3 to the financial statements.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 26 -
8
Financial instruments

Financial instruments RPI and interest rate swaps

 

In May 2005 the group entered into a 22 year fixed RPI swap arrangement designed to restrict its exposure to the effect of RPI fluctuations on its income. The swap was affected on a notional total of £114 million payable in six-monthly amounts between October 2005 and October 2027.

 

In order to hedge against interest variations on the loan, in March 2010 the group entered into a 19 year fixed interest rate swap arrangement with the bank to hedge its exposure to the effect of interest rate fluctuations. The swap was affected on a maximum notional amount of £64.8 million payable in six-monthly intervals between March 2010 and September 2028. Sums are exchanged reflecting the difference between floating and fixed interest rates, calculated on a predetermined notional principal amount.

 

The fair value of derivatives used for hedging in the Balance Sheet are:            

 

Group
2024
2023
£000
£000
Liabilities
RPI swap liability at period end
7,929
9,858
Interest swap (asset)/liability at period end
(105)
261
7,824
10,119
The movement in the fair value of derivatives used for hedging are:
2024
2023
£000
£000
Recognised through Other Comprehensive Income - RPI swap
(4,305)
(4,015)
Recognised through Other Comprehensive Income - Interest Rate swap
(63)
431
(4,368)
(3,584)
2024
2023
£000
£000
Recognised through P&L - RPI swap
2,376
2,413
Recognised through P&L - Interest Rate swap
(303)
(238)
2,073
2,175
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 27 -
9
Debtors
Group
Company
2024
2023
2024
2023
Amounts falling due within one year:
£000
£000
£000
£000
Trade debtors
11,971
10,875
-
0
-
0
Amounts owed by group undertakings
-
-
2
2
Finance debtor
4,511
3,984
-
0
-
0
Consortium Relief interest receivable
493
399
Prepayments and accrued income
111
90
-
0
-
0
17,086
15,348
2
2
Amounts falling due after more than one year:
Consortium relief receivable (note 7)
1,677
1,677
-
-
Loans receivable (note 7)
1,231
1,231
-
-
Finance debtor
26,918
31,427
-
0
-
0
29,826
34,335
-
-
Total debtors
46,912
49,683
2
2
The loans are repayable on demand or at the end of the project term, and bear interest at bank base rate plus 2.5% per annum.
10
Creditors: amounts falling due within one year
Group
Company
2024
2023
2024
2023
Notes
£000
£000
£000
£000
Senior secured loan
5,401
4,617
-
0
-
0
Trade creditors
29
47
-
0
-
0
Corporation tax payable
1,147
3,733
-
0
-
0
Other taxation and social security
1,598
1,462
-
-
Derivative financial instruments
2,524
-
0
-
0
-
0
Accruals and deferred income
11,045
10,380
-
0
-
0
21,744
20,239
-
0
-
0
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 28 -
11
Creditors: amounts falling due after more than one year
Group
Company
2024
2023
2024
2023
Notes
£000
£000
£000
£000
Senior secured loan
13
21,038
26,438
-
0
-
0
Derivative financial instruments
9
5,300
10,119
-
0
-
0
26,338
36,557
-
-
13
Loans and overdrafts
Group
Company
2024
2023
2024
2023
£000
£000
£000
£000
Senior secured loan
26,439
31,055
-
0
-
0
Payable within one year
5,401
4,617
-
0
-
0
Payable after one year
21,038
26,438
-
0
-
0

The senior secured loan represents amounts borrowed under a facility agreement with Barclays Bank.

 

The loan bears interest at a margin of 2.1% over a fixed swap rate of 4.343% plus applicable credit spread and is repayable in six-monthly instalments between 2010 and 2029. The loan is secured by fixed and floating charges over the property, assets and rights of the company, and has certain covenants attached.

13
Deferred taxation

The following are the major deferred tax liabilities and assets recognised by the group and company, and movements thereon:

Liabilities
Liabilities
2024
2023
Group
£000
£000
Accelerated capital allowances
3,186
3,597
Fair value of financial instruments
(1,957)
(2,530)
1,229
1,067
The company has no deferred tax assets or liabilities.
HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
13
Deferred taxation
(Continued)
- 29 -
Group
Company
2024
2024
Movements in the year:
£000
£000
Liability at 1 January 2024
1,067
-
Credit to profit or loss
(412)
-
Deferred tax relating to other comprehensive income
574
-
Liability at 31 December 2024
1,229
-

The accelerated capital allowances balance relates to the difference between the accounting and taxation treatments of capital items. The liability will unwind over the period that the group is subject to the PFI contract as noted in the Principal Activities on page 3.

 

The company has also contracted to hedge certain cash flows with third parties over the period of the PFI concession. The above fair value of financial instruments balance relates to the tax impact from the fair value accounting of the hedge liabilities. This balance will also unwind over the period of the concession.

14
Share capital
Group and company
2024
2023
2024
2023
Ordinary share capital
Number
Number
£000
£000
Issued and fully paid
Ordinary shares of £1 each
841,002
841,002
841
841
15
Reserves

Called-up share capital - represents the nominal value of shares that have been issued.

 

Profit and loss - includes all current and prior period profits and losses.

 

Cash flow hedge reserve - used to record transactions arising from the group’s cash flow hedging arrangements.

16
Related party transactions
Transactions with related parties

Dalmore Capital Fund LP charged the company £134,000 (2023: £129,000) for Directors' fees. Dalmore Capital Fund LP are considered to be a related party due to their control of the company.

HEALTH MANAGEMENT (CARLISLE) HOLDINGS LIMITED
NOTES TO THE GROUP FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
16
Related party transactions
(Continued)
- 30 -

The following amounts were outstanding at the reporting end date:

Amounts due from related parties
2024
2023
Balance
Balance
£000
£000
Group
Dalmore Capital (Carlisle 1) Limited - Loan receivable
1,231
1,231
Dalmore Capital (Carlisle 1) Limited - Consortium relief receivable
1,677
1,677
Dalmore Capital (Carlisle 1) Limited - Consortium relief interest
493
399
17
Cash generated from group operations
2024
2023
£000
£000
Profit after taxation
3,342
3,046
Adjustments for:
Taxation charged
1,620
2,879
Finance costs
1,920
2,264
Investment income
(3,806)
(4,025)
Movements in working capital:
Decrease in debtors
2,864
2,875
Increase/(decrease) in creditors
786
(925)
Cash generated from operations
6,726
6,114
18
Analysis of changes in net funds - group
1 January 2024
Cash flows
Other non-cash changes
31 December 2024
£000
£000
£000
£000
Cash at bank and in hand
11,493
(2,920)
-
8,573
Senior Debt
(31,055)
4,616
-
(26,439)
Finance Receivable
35,411
-
(3,982)
31,429
15,849
1,696
(3,982)
13,563
19
Parent undertaking and controlling parties

In the directors’ opinion there is no ultimate controlling party.

The ultimate parent company is Dalmore Capital Fund LP, acting by their general manager, Dalmore Capital Limited.

These are the smallest and largest group accounts that are prepared of which the company is a member. Copies of the financial statements of Health Management (Carlisle) Holdings Limited are available from 1 Park Row, Leeds, LS1 5AB.

2024-12-312024-01-01falsefalseCCH SoftwareCCH Accounts Production 2024.310Matthew TempletonB LoveD JonesResolis Limitedfalse03561960bus:Consolidated2024-01-012024-12-31035619602024-01-012024-12-3103561960bus:Director22024-01-012024-12-3103561960bus:Director32024-01-012024-12-3103561960bus:CompanySecretary12024-01-012024-12-3103561960bus:Director12024-01-012024-12-3103561960bus:RegisteredOffice2024-01-012024-12-3103561960bus:Consolidated2024-12-31035619602024-12-3103561960bus:Consolidated2023-01-012023-12-3103561960bus:Consolidated2023-12-3103561960core:ShareCapitalbus:Consolidated2024-12-3103561960core:ShareCapitalbus:Consolidated2023-12-3103561960core:HedgingReservebus:Consolidated2024-12-3103561960core:ShareCapital2024-12-3103561960core:ShareCapital2023-12-3103561960core:RetainedEarningsAccumulatedLosses2024-12-3103561960core:ShareCapitalbus:Consolidated2022-12-3103561960core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-12-3103561960core:ShareCapital2022-12-3103561960core:RetainedEarningsAccumulatedLosses2022-12-3103561960core:RetainedEarningsAccumulatedLosses2023-12-31035619602023-12-3103561960core:RevenueReservesInvestmentFundsOnlybus:Consolidated2023-01-012023-12-3103561960core:RetainedEarningsAccumulatedLossesbus:Consolidated2024-01-012024-12-3103561960core:UKTaxbus:Consolidated2024-01-012024-12-3103561960core:UKTaxbus:Consolidated2023-01-012023-12-3103561960bus:Consolidated12024-01-012024-12-3103561960bus:Consolidated12023-01-012023-12-3103561960bus:Consolidated22024-01-012024-12-3103561960bus:Consolidated22023-01-012023-12-3103561960core:CurrentFinancialInstruments2024-12-3103561960core:CurrentFinancialInstruments2023-12-3103561960core:Non-currentFinancialInstrumentsbus:Consolidated2024-12-3103561960core:Non-currentFinancialInstrumentsbus:Consolidated2023-12-3103561960core:Non-currentFinancialInstruments2024-12-3103561960core:Non-currentFinancialInstruments2023-12-3103561960core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3103561960core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3103561960core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2024-12-3103561960core:Non-currentFinancialInstrumentscore:AfterOneYearbus:Consolidated2023-12-3103561960core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3103561960core:Non-currentFinancialInstrumentscore:AfterOneYear2023-12-3103561960core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2024-12-3103561960core:CurrentFinancialInstrumentscore:WithinOneYearbus:Consolidated2023-12-3103561960core:CurrentFinancialInstrumentsbus:Consolidated2023-12-3103561960core:CurrentFinancialInstrumentsbus:Consolidated2024-12-3103561960bus:PrivateLimitedCompanyLtd2024-01-012024-12-3103561960bus:FRS1022024-01-012024-12-3103561960bus:Audited2024-01-012024-12-3103561960bus:ConsolidatedGroupCompanyAccounts2024-01-012024-12-3103561960bus:FullAccounts2024-01-012024-12-31xbrli:purexbrli:sharesiso4217:GBP